Cargando…

Modulation of Post-Traumatic Immune Response Using the IL-1 Receptor Antagonist Anakinra for Improved Visual Outcomes

The purpose of this study was to characterize acute changes in inflammatory pathways in the mouse eye after blast-mediated traumatic brain injury (bTBI) and to determine whether modulation of these pathways could protect the structure and function of retinal ganglion cells (RGC). The bTBI was induce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Evans, Lucy P., Woll, Addison W., Wu, Shu, Todd, Brittany P., Hehr, Nicole, Hedberg-Buenz, Adam, Anderson, Michael G., Newell, Elizabeth A., Ferguson, Polly J., Mahajan, Vinit B., Harper, Matthew M., Bassuk, Alexander G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249480/ https://www.ncbi.nlm.nih.gov/pubmed/32056479 http://dx.doi.org/10.1089/neu.2019.6725

Ejemplares similares

Sex Does Not Influence Visual Outcomes After Blast-Mediated Traumatic Brain Injury but IL-1 Pathway Mutations Confer Partial Rescue
por: Evans, Lucy P., et al.
Publicado: (2020)

Blast Preconditioning Protects Retinal Ganglion Cells and Reveals Targets for Prevention of Neurodegeneration Following Blast-Mediated Traumatic Brian Injury
por: Harper, Matthew M., et al.
Publicado: (2019)

Traumatic brain injury results in unique microglial and astrocyte transcriptomes enriched for type I interferon response
por: Todd, Brittany P., et al.
Publicado: (2021)

Combined Blockade of Interleukin-1α and -1β Signaling Protects Mice from Cognitive Dysfunction after Traumatic Brain Injury
por: Newell, Elizabeth A., et al.
Publicado: (2018)

Acute vitreoretinal trauma and inflammation after traumatic brain injury in mice
por: Evans, Lucy P., et al.
Publicado: (2018)

A Mouse Model for Juvenile, Lateral Fluid Percussion Brain Injury Reveals Sex-Dependent Differences in Neuroinflammation and Functional Recovery
por: Newell, Elizabeth A., et al.
Publicado: (2020)

Recurrent poliserositis succesfully treated with IL-1 receptor antagonist Anakinra
por: Lovillo, MS Camacho, et al.
Publicado: (2011)

Selective neuroimmune modulation by type I interferon drives neuropathology and neurologic dysfunction following traumatic brain injury
por: Todd, Brittany P., et al.
Publicado: (2023)

The IL-1 Antagonist Anakinra Attenuates Glioblastoma Aggressiveness by Dampening Tumor-Associated Inflammation
por: Hübner, Max, et al.
Publicado: (2020)

The Use of IL-1 Receptor Antagonist (Anakinra) in Idiopathic Recurrent Pericarditis: A Narrative Review
por: Baskar, Shankar, et al.
Publicado: (2016)

IL‐1 receptor antagonist, anakinra, prevents myocardial dysfunction in a mouse model of Kawasaki disease vasculitis and myocarditis
por: Gorelik, M., et al.
Publicado: (2019)

In trans variant calling reveals enrichment for compound heterozygous variants in genes involved in neuronal development and growth.
por: Cox, Allison J., et al.
Publicado: (2019)

A novel de novo CAPN5 mutation in a patient with inflammatory vitreoretinopathy, hearing loss, and developmental delay
por: Velez, Gabriel, et al.
Publicado: (2018)

Monozygotic twins with CAPN5 autosomal dominant neovascular inflammatory vitreoretinopathy
por: Rowell, Hannah A, et al.
Publicado: (2012)

Interleukin-1 Antagonist Anakinra in Amyotrophic Lateral Sclerosis—A Pilot Study
por: Maier, André, et al.
Publicado: (2015)

ProSave: an application for restoring quantitative data to manipulated subsets of protein lists
por: Machlab, Daniel A., et al.
Publicado: (2018)

A pilot study of IL-1 inhibition by anakinra in acute gout
por: So, Alexander, et al.
Publicado: (2007)

Recessive coding and regulatory mutations in FBLIM1 underlie the pathogenesis of chronic recurrent multifocal osteomyelitis (CRMO)
por: Cox, Allison J., et al.
Publicado: (2017)

Correction: Recessive coding and regulatory mutations in FBLIM1 underlie the pathogenesis of chronic recurrent multifocal osteomyelitis (CRMO)
por: Cox, Allison J., et al.
Publicado: (2017)

Proteomic analysis of intermediate uveitis suggests myeloid cell recruitment and implicates IL-23 as a therapeutic target
por: Sepah, Yasir J., et al.
Publicado: (2020)

Treatment of cytokine storm syndrome with IL‐1 receptor antagonist anakinra in a patient with ARDS caused by COVID‐19 infection: A case report
por: Kaps, Leonard, et al.
Publicado: (2020)

The interleukin-1 receptor antagonist anakinra improves endothelial dysfunction in streptozotocin-induced diabetic rats
por: Vallejo, Susana, et al.
Publicado: (2014)

Visual Outcomes in Experimental Rodent Models of Blast-Mediated Traumatic Brain Injury
por: Evans, Lucy P., et al.
Publicado: (2021)

Precision Medicine: Genetic Repair of Retinitis Pigmentosa in Patient-Derived Stem Cells
por: Bassuk, Alexander G., et al.
Publicado: (2016)

Comparison of the effects of erythropoietin and anakinra on functional recovery and gene expression in a traumatic brain injury model
por: Anderson, Gail D., et al.
Publicado: (2013)

Calpain-5 gene expression in the mouse eye and brain
por: Schaefer, Kellie, et al.
Publicado: (2017)

Gain-of-function mutations in a member of the Src family kinases cause autoinflammatory bone disease in mice and humans
por: Abe, Koichiro, et al.
Publicado: (2019)

Autism Linked to Increased Oncogene Mutations but Decreased Cancer Rate
por: Darbro, Benjamin W., et al.
Publicado: (2016)

VCAN Canonical Splice Site Mutation is Associated With Vitreoretinal Degeneration and Disrupts an MMP Proteolytic Site
por: Tang, Peter H., et al.
Publicado: (2019)

Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report
por: Franzetti, Marco, et al.
Publicado: (2020)

Blast-Mediated Traumatic Brain Injury Exacerbates Retinal Damage and Amyloidosis in the APPswePSENd19e Mouse Model of Alzheimer's Disease
por: Harper, Matthew M., et al.
Publicado: (2019)

Familial mediterranean fever and pauciimmune renal vasculitis: the role of IL-1 blockade (Anakinra)
por: Lovillo, MS Camacho, et al.
Publicado: (2011)

7.3 Successful use of anakinra, a soluble IL-1 receptor antagonist, in pediatric rheumatic diseases associated macrophage activation syndrome/reactive hemophagocytic lymphohistiocytosis
por: Miettunen, PM, et al.
Publicado: (2008)

The IL-1 receptor antagonist anakinra (kineret®) stabilizes the NLRP3 mutation-specific risk for hearing loss in patients with severe cryopyrin-associated periodic syndromes (CAPS)
por: Leinonen, Mika, et al.
Publicado: (2014)

Proteomic insight into the pathogenesis of CAPN5-vitreoretinopathy
por: Velez, Gabriel, et al.
Publicado: (2019)

Anakinra for patients with COVID-19
por: Maoujoud, Omar, et al.
Publicado: (2020)

Anakinra for patients with COVID-19
por: Valette, Xavier, et al.
Publicado: (2020)

Anakinra for patients with COVID-19
por: Martin-Silva, Nicolas, et al.
Publicado: (2020)

Effect of anakinra in COVID-19
por: Kooistra, Emma J, et al.
Publicado: (2020)

Anakinra: Jaundice: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hkl0tp4anp6u6d5t3ij2brcd2d